- Home
- VYGR vs MQT Comparison
VYGR vs MQT Comparison
Compare VYGR & MQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- MQT
- Stock Information
- Founded
- VYGR 2013
- MQT 1992
- Country
- VYGR United States
- MQT United States
- Employees
- VYGR N/A
- MQT N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- MQT Investment Bankers/Brokers/Service
- Sector
- VYGR Health Care
- MQT Finance
- Exchange
- VYGR Nasdaq
- MQT Nasdaq
- Market Cap
- VYGR 206.9M
- MQT 207.5M
- IPO Year
- VYGR 2015
- MQT N/A
- Fundamental
- Price
- VYGR $3.36
- MQT $9.57
- Analyst Decision
- VYGR Strong Buy
- MQT
- Analyst Count
- VYGR 7
- MQT 0
- Target Price
- VYGR $14.50
- MQT N/A
- AVG Volume (30 Days)
- VYGR 725.5K
- MQT 52.5K
- Earning Date
- VYGR 08-06-2025
- MQT 01-01-0001
- Dividend Yield
- VYGR N/A
- MQT 4.60%
- EPS Growth
- VYGR N/A
- MQT N/A
- EPS
- VYGR N/A
- MQT N/A
- Revenue
- VYGR $42,580,000.00
- MQT N/A
- Revenue This Year
- VYGR N/A
- MQT N/A
- Revenue Next Year
- VYGR $107.07
- MQT N/A
- P/E Ratio
- VYGR N/A
- MQT N/A
- Revenue Growth
- VYGR N/A
- MQT N/A
- 52 Week Low
- VYGR $2.65
- MQT $8.59
- 52 Week High
- VYGR $8.28
- MQT $10.67
- Technical
- Relative Strength Index (RSI)
- VYGR 49.16
- MQT 55.46
- Support Level
- VYGR $3.30
- MQT $9.47
- Resistance Level
- VYGR $3.49
- MQT $9.56
- Average True Range (ATR)
- VYGR 0.21
- MQT 0.07
- MACD
- VYGR -0.02
- MQT 0.00
- Stochastic Oscillator
- VYGR 33.33
- MQT 69.23
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.